News | Heart Valve Technology | May 16, 2016

4Tech Partnering With Renowned Cardiologist to Accelerate Transcatheter Tricuspid Device Development

Company announces agreement with Jean-Claude Laborde to serve as R&D and clinical advisor

4Tech Inc., TriCinch transcatheter tricuspid valve repair device, Jean-Claude Laborde

Image courtesy of 4Tech Inc.

May 16, 2016 — 4Tech Inc. announced its partnership with Jean-Claude Laborde, M.D., as a research and development (R&D) and clinical advisor focused on fast-forwarding the TriCinch Generation Two and Generation Three programs. The company calls TriCinch the world’s first transcatheter device for repair of the tricuspid heart valve.

Laborde is an internationally recognized cardiologist and one of the world leaders in transcatheter aortic valve implantation (TAVI). He holds numerous patents for novel medical devices that have changed how cardiologists practice medicine and has designed new medical procedures to treat specific cardiac conditions. Laborde is a key opinion leader in interventional cardiology, having spoken around the world about TAVI and other new medical procedures and trained hundreds of physicians internationally.

Tricuspid regurgitation represents a significant unmet clinical need,” said Laborde, who previously supported the development of the CoreValve device when it was emerging, serving as chief medical officer until CoreValve was purchased by Medtronic in 2009. “4Tech is the sole company that is 100-percent-focused on repairing the tricuspid valve and possesses in-depth knowledge of the tricuspid valve anatomy and pathology. I am very proud to be a part of 4Tech.”

Laborde continues to provide proctoring support for TAVI devices. In addition, he has also been involved in training and teaching cardiologists and interventional cardiologists how to use TAVI devices, how to properly select patients and establish safe and effective protocols for hospitals and clinics. 

Laborde was also intimately involved in the development of the Transcatheter Mitral Valve Replacement solution developed by CardiAQ, which was acquired by Edwards Lifesciences in 2015.

For more information: www.4techtricuspid.com

Related Content

Abbott Tricuspid Valve Repair System Reduces Tricuspid Regurgitation at 30 Days
News | Heart Valve Technology | June 11, 2019
June 11, 2019 — Abbott recently announced positive late-breaking data from its TRILUMINATE...
DSM and SAT Partnering to Develop Next-Generation, Cost-Effective Heart Valve
News | Heart Valve Technology | June 04, 2019
Royal DSM recently announced a collaboration with Strait Access Technologies (SAT), to develop the world’s first...

The MitraClip is one example of a transcatheter mitral valve repair or replacement (TMVR) device used in the structural heart repair program at Henry Ford Hospital.

Podcast | Heart Valve Technology | May 31, 2019
Marvin Eng, M.D., structural fellowship director at Henry Ford Health System, and William O'Neill, M.D., director of
Illustration showing the catheter steps for the LAMPOON procedure designed to prevent left ventricular outflow tract (LVOT) obstruction . From Dr. Jaffar M. Khan and the Laboratory of Cardiovascular Intervention, led by Dr. Robert J. Lederman.

Figure 1: Illustration showing the catheter steps for the LAMPOON procedure. From Dr. Jaffar M. Khan and the Laboratory of Cardiovascular Intervention, led by Dr. Robert J. Lederman.

Feature | Heart Valve Technology | May 22, 2019
Researchers at the National, Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH
Edwards Announces Research Milestones for Pascal Transcatheter Mitral Valve Program
News | Heart Valve Technology | May 22, 2019
Edwards Lifesciences Corp. announced strategic clinical and regulatory milestones for its Edwards Pascal transcatheter...
Videos | Heart Valve Technology | May 20, 2019
A demonstration of how to calculate the neo-left ventricular outflow tract (neo-LVOT) on CT imaging for a transcathet
Study Finds TAVR Can Be Considered for Patients in All Surgical Risk Classes
News | Heart Valve Technology | May 08, 2019
Transcatheter aortic valve replacement (TAVR) has been studied as an alternative to surgical aortic valve replacement...
Boston Scientific Receives FDA Approval for Lotus Edge Aortic Valve System
Feature | Heart Valve Technology | April 23, 2019 | Dave Fornell, Editor
Boston Scientific Corp. announced it has received U.S. Food and Drug Administration (FDA) approval for the Lotus Edge...
New Consensus Document Explores Optimized Care for Valvular Heart Disease Patients
News | Heart Valve Technology | April 22, 2019
April 22, 2019 — Five cardiovascular professional societies released a new consensus document on optimizing care for
Mick Jagger Recovering After TAVR Procedure
News | Heart Valve Technology | April 08, 2019 | Jeff Zagoudis, Associate Editor
Rolling Stones frontman Mick Jagger is reportedly recovering after undergoing a transcatheter aortic valve valve...
Overlay Init